Thomas Powles, MBBS, MCRP, MD

home / authors / thomas-powles-md-phd

Articles

Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC

Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC

Thomas Powles, MBBS, MCRP, MD
July 19th 2025

The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.

Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCC

Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCC

Thomas Powles, MBBS, MCRP, MD
July 18th 2025

Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.

Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma

Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Thomas Powles, MBBS, MCRP, MD
April 19th 2022

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

Thomas Powles, MD, PhD on Next Steps for Avelumab and the Future of Treatment for Urothelial Cancer

Thomas Powles, MD, PhD on Next Steps for Avelumab and the Future of Treatment for Urothelial Cancer

Thomas Powles, MBBS, MCRP, MD
June 3rd 2020

The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 23-Year-Old Male With Right Leg Pain
Published: April 26th 2018 | Updated: July 25th 2025
A 23-Year-Old Male With Right Leg Pain